Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jubilant PharmovaBOM:530019 +0.21%71 Current Ratio is 1.62 as of Mar. 2026, which is 19% below its 10-year median of 1.99. GuruFocus rates BOM:530019 with a GF Score™ of 71/100 and a GF Value™ of ₹1,059.60 (Fairly Valued). The stock has 5 warning signs investors should review. Among 999 Drug Manufacturers companies, Jubilant Pharmova ranks worse than 62.26% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Jubilant Pharmova's current ratio for the quarter that ended in Mar. 2026 was 1.62.
Jubilant Pharmova has a current ratio of 1.62. It generally indicates good short-term financial strength.
The historical rank and industry rank for Jubilant Pharmova's Current Ratio or its related term are showing as below:
BOM:530019'
s Current Ratio Range Over the Past 10 Years
Min: 1.59 Med: 1.99 Max: 2.82
Current: 1.62
During the past 13 years, Jubilant Pharmova's highest Current Ratio was 2.82. The lowest was 1.59. And the median was 1.99.
BOM:530019's Current Ratio is ranked worse than 62.26% of 999
companies
in the Drug Manufacturers industry
Industry Median: 2
vs BOM:530019: 1.62
Jubilant Pharmova (BOM:530019) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Jubilant Pharmova Current Ratio Related Terms
Jubilant Pharmova Current Ratio Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Current Ratio distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a Current Ratio of 1.62 as of Mar. 2026. This is 19% below median its historical median of 1.99. Over the past decade, Jubilant Pharmova's Current Ratio has ranged from 1.59 to 2.82. According to the industry distribution chart, Jubilant Pharmova ranks #622 out of 999 companies in the Drug Manufacturers industry, placing it in the top 62.3%.
Is Jubilant Pharmova's Current Ratio too high?
Jubilant Pharmova's current Current Ratio of 1.62 is 19% below median its 10-year median of 1.99. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 2.82. The Drug Manufacturers industry median Current Ratio is 2.00. Jubilant Pharmova's value of 1.62 is 19% below this industry median. Based on the distribution chart, Jubilant Pharmova ranks #622 out of 999 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jubilant Pharmova has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #622 out of 999 companies for Current Ratio. This places Jubilant Pharmova in the lower half of its industry. The industry median Current Ratio is 2.00. Jubilant Pharmova's value of 1.62 is 19% below this benchmark. Historically, Jubilant Pharmova's own Current Ratio has ranged from 1.59 to 2.82 over the past decade. While the company's 10-year median is 1.99 vs. the industry median of 2.00, Jubilant Pharmova has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current Current Ratio of 1.62 is 19% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current Current Ratio is 1.62, which is 19% below median its own 10-year median of 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,059.60, compared to a current price of ₹1,022.25 — trading 3.5% below its estimated fair value. The current Current Ratio is 1.62, which is 19% below median its 10-year median of 1.99 and 19% below the Drug Manufacturers industry median of 2.00. Jubilant Pharmova's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Current Ratio is 1.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹1,022.25 is trading 3.5% below its estimated GF Value™ of ₹1,059.60.
GuruFocus considers Jubilant Pharmova to be Fairly Valued.
Key valuation signals for BOM:530019:
Current Ratio: 1.62 (19% below median its 10-year median of 1.99)
GF Value™: ₹1,059.60 vs. price of ₹1,022.25 (3.5% below fair value)
Industry Position: 19% below the Drug Manufacturers median (#622 of 999)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
71GF Score
Get the complete analysis for BOM:530019
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
